Explore this article's sources with AI
Follow PeptideMethods on Google
Semaglutide Adverse Effects in 12 RCTs
A scoping review mapped adverse events across 12 semaglutide RCT reports but found no direct trial evidence for oral-health risk.
Why we wrote this. The review is easy to overread as a dental-risk estimate or route comparison. We separate repeated systemic reporting from the absence of direct oral-health measurement.
In this article (5 sections)
A 2026 scoping review mapped adverse events reported in 12 randomized controlled trial publications involving oral or injected semaglutide. The review enrolled 0 new participants and generated 0 original patient outcomes. It found that gastrointestinal events dominated the trial reports, while the trials supplied too little direct oral-health evidence to support a dental-risk estimate[1]. This is an evidence map, not a pooled meta-analysis.
The review searched PubMed, Scopus and Web of Science for English-language randomized trials published from 2019 through 2025. From 630 records, the authors removed 10 duplicates, screened 620 records and included 12 reports. Two reviewers screened and extracted the evidence independently, with a third reviewer available for disagreements. The protocol was registered in the Open Science Framework[2].
What the review actually counted
The included trials involved adults with type 2 diabetes, obesity or both. Treatment lasted 21 to 68 weeks, usually followed by another four to nine weeks of observation. Seven reports studied subcutaneous administration, three studied oral administration and two included oral and subcutaneous approaches[2]. Different comparators, doses and populations make those reports unsuitable for one simple cross-trial rate.
Nausea appeared in all 12 reports and diarrhea in 11. Constipation appeared in nine reports and vomiting in eight. These are report counts. They do not say what proportion of all semaglutide-treated participants experienced an event, and the review did not calculate either a pooled risk ratio or an absolute event rate[3].
The review also mapped pancreatitis in five reports, hepatobiliary events in three and gallbladder disease in three. Presence in a trial report does not by itself establish an excess over the comparator. The underlying table contains different treatment groups and comparators, so each safety question would require trial-level event counts and a defined synthesis method[2].
Oral-health evidence was the central gap
None of the included trials was designed to investigate oral or dental outcomes directly. Dry mouth appeared in one report. Dental caries appeared in one other report, including across semaglutide doses and in the placebo group. Another isolated submandibular abscess occurred in a placebo participant, not a semaglutide group[2]. Sparse incidental reporting cannot establish incidence, comparison with placebo or a biological pathway.
An adverse-event table and a planned dental assessment answer different questions. A trial may record a volunteered complaint without measuring salivary flow or periodontal status. It may not record baseline oral disease. If investigators did not define and examine an oral endpoint, a blank table cell cannot be read as proof that the event never occurred.
The authors concluded that available randomized evidence was insufficient for conclusions about semaglutide-associated oral adverse events. That conclusion is narrower than saying semaglutide has no oral effects. It means the selected trials did not measure the question well enough. A separate published FAERS analysis can identify reporting signals, but spontaneous reports also cannot supply incidence or causation[2].
Oral and injected routes were not compared fairly
The paper noted high adverse-event counts in both oral-dose and subcutaneous studies. It also discussed a higher frequency with oral semaglutide. That observation should not be treated as a randomized oral-versus-injection result: the route groups came from different trials with different doses, comparators, durations and participant characteristics[3]. No pooled route comparison was reported.
A publication count is especially limited for uncommon events. One large trial and one small trial each count as one report, while a study that does not mention an event may have used a different collection or reporting threshold. The scoping design maps where events appeared. It does not estimate which route is safer or rank formulations for an individual patient.
How strong is this safety map?
The review followed PRISMA guidance for scoping reviews, registered its protocol and used independent screening. Full text also reports that the authors received no specific funding and declared no competing interests[2]. Those safeguards help readers understand the process, but they do not repair limits in the underlying outcome collection.
The search excluded non-English publications and focused on randomized trials. That choice reduces some confounding but can miss longer routine-care exposure, rare-event surveillance and dental studies outside the selected trial set. The search strategy was developed by the authors and was not externally peer reviewed. No formal certainty grade or pooled estimate was reported.
The most defensible interpretation has two layers. Gastrointestinal adverse events were repeatedly reported across semaglutide RCTs, although this review did not produce one combined rate. Oral and dental outcomes remain an evidence gap because the trials were not designed to measure them directly. Those layers should not be collapsed into either a blanket safety assurance or a new dental warning.
What this means for readers
This paper cannot determine whether semaglutide caused a particular person's symptom. It also cannot compare oral and injected formulations for that person. Dry mouth, caries, abdominal symptoms and gallbladder events require clinical context, including timing, other medicines, underlying diabetes, hydration and pre-existing oral health.
Future randomized studies would need prespecified oral outcomes, baseline dental examinations, consistent follow-up and transparent comparator data. Until then, the review is useful chiefly for showing where trial safety reporting is dense and where it is thin. Twelve RCT reports provide a broad systemic map. They do not provide a direct oral-health answer.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Was this a new semaglutide trial?
No. It was a scoping review of 12 randomized trial reports. The review enrolled no new participants and produced no original patient outcomes.
What adverse events appeared most consistently?
Nausea appeared in all 12 included reports and diarrhea in 11. These are publication counts, not pooled patient rates or comparative risks.
Did the review prove semaglutide causes dental problems?
No. None of the included trials directly investigated oral or dental outcomes. Dry mouth and dental caries were sparsely and incidentally reported, so the review could not estimate oral-health risk.
Sources
- [1]Muknickas et al. Semaglutide adverse effects scoping review. PMID 43034163.Tier 1 · primary↩
- [2]PMC full text for the semaglutide adverse effects scoping review.Tier 1 · primary↩
- [3]BMC Oral Health full text and safety table for the scoping review.Tier 1 · primary↩
No revisions yet. First published .